During the last years, CDK4/6 inhibitors have changed the treatment landscape of hormone receptor‐positive and HER‐2‐negative breast tumors offering large progression‐free intervals to many patients with invasive breast cancer. Here, NR4A1 is linked to invasive breast carcinoma.